# Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

> **NCT04575675** · PHASE4 · COMPLETED · sponsor: **Cheng-Hsin General Hospital** · enrollment: 78 (actual)

## Conditions studied

- Hypotension
- Heart Failure

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Sacubitril-Valsartan
- **DRUG:** Beta blocker
- **DRUG:** Mineralocorticoid Receptor Antagonist
- **DEVICE:** Cardiac resynchronization therapy and/or implantable cardioverter defibrillator

## Key facts

- **NCT ID:** NCT04575675
- **Lead sponsor:** Cheng-Hsin General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-29
- **Primary completion:** 2020-11-25
- **Final completion:** 2020-12-30
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04575675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04575675, "Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04575675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*